A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Latest Information Update: 11 Feb 2026
At a glance
- Drugs BMS 986506 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 30 Dec 2025 Planned initiation date (estimated date of first patient enrollment) changed from 15 Dec 2025 to 31 Dec 2025.
- 30 Dec 2025 Status changed from not yet recruiting to recruiting.
- 03 Oct 2025 New trial record